{"commentary":{"count":194,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":67,"podcast":67,"x_thread":60},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02743494\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate 577","nct_id":"NCT02743494","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-577-nct02743494. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CheckMate 577","arms":[{"description":null,"label":"Nivolumab","type":"EXPERIMENTAL"},{"description":null,"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2024-11-07","type":"ACTUAL"},"conditions":["Advanced Cancer"],"enrollment":{"count":794,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"last_update":"2025-11-18","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-05-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-free Survival (DFS)","timeFrame":"From randomization to the date of recurrence or death (up to approximately 46 months)"}],"references":[{"citation":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lievre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.","pmid":"33789008","type":"DERIVED"}],"start_date":{"date":"2016-07-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer","url":"https://clinicaltrials.gov/study/NCT02743494"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-577-nct02743494"}